Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Diabetes

  Free Subscription


12.07.2021

1 Ann Intern Med
1 Atherosclerosis
1 Biochem Biophys Res Commun
1 BMJ
1 Circ Genom Precis Med
1 Clin Chem
2 Diabet Med
1 Diabetes
3 Diabetes Care
32 Diabetes Obes Metab
1 Diabetologia
1 Invest Ophthalmol Vis Sci
1 J Clin Endocrinol Metab
3 J Diabetes Complications
1 J Hypertens
2 J Nutr
3 Lancet
1 Metabolism
1 Pediatr Diabetes
1 PLoS Med
2 PLoS One
1 Retina
1 Transplant Proc


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Intern Med

  1. RAJAGOPAL S, Cheskin LJ
    In overweight or obese adults without diabetes, semaglutide increased weight loss and GI disorders.
    Ann Intern Med. 2021 Jul 6. doi: 10.7326/ACPJ202107200.
    PubMed         Abstract available


    Atherosclerosis

  2. RAU M, Thiele K, Korbinian Hartmann NU, Mollmann J, et al
    Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study.
    Atherosclerosis. 2021;330:8-13.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  3. SANCHEZ PKM, Khazaei M, Gatineau E, Geravandi S, et al
    LDHA is enriched in human islet alpha cells and upregulated in type 2 diabetes.
    Biochem Biophys Res Commun. 2021;568:158-166.
    PubMed         Abstract available


    BMJ

  4. TAYLOR R, Ramachandran A, Yancy WS Jr, Forouhi NG, et al
    Nutritional basis of type 2 diabetes remission.
    BMJ. 2021;374:n1449.
    PubMed        


    Circ Genom Precis Med

  5. LU Y, Dimitrov L, Chen SH, Bielak LF, et al
    Multiethnic Genome-wide Association Study of Subclinical Atherosclerosis in Individuals with Type 2 Diabetes.
    Circ Genom Precis Med. 2021 Jul 9. doi: 10.1161/CIRCGEN.120.003258.
    PubMed         Abstract available


    Clin Chem

  6. KAMSTRUP PR
    Lipoprotein(a) and Cardiovascular Disease.
    Clin Chem. 2020 Nov 25. pii: 6000718. doi: 10.1093.
    PubMed         Abstract available


    Diabet Med

  7. ROTBAIN CUROVIC V, Magalhaes P, He T, Hansen TW, et al
    Urinary proteome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials.
    Diabet Med. 2021 Jul 6:e14634. doi: 10.1111/dme.14634.
    PubMed         Abstract available

  8. PATTON SR, Feldman K, Majidi S, Noser A, et al
    Identifying HbA1c Trajectories and Modifiable Risk Factors of Trajectories in 5-9-year-olds with Recent-Onset Type 1 Diabetes from the United States.
    Diabet Med. 2021 Jul 8:e14637. doi: 10.1111/dme.14637.
    PubMed         Abstract available


    Diabetes

  9. WANG Y, Niu A, Pan Y, Cao S, et al
    Profile of podocyte translatome during development of type 2 and type 1 diabetic nephropathy using podocyte-specific TRAP mRNA RNA-seq.
    Diabetes. 2021 Jul 7. pii: db21-0110. doi: 10.2337/db21-0110.
    PubMed         Abstract available


    Diabetes Care

  10. STEMPNIEWICZ N, Vassalotti JA, Cuddeback JK, Ciemins E, et al
    Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations.
    Diabetes Care. 2021 Jul 7. pii: dc20-2715. doi: 10.2337/dc20-2715.
    PubMed         Abstract available

  11. SPANAKIS EK, Yoo A, Ajayi ON, Siddiqui T, et al
    Excess Mortality in COVID-19-Positive Versus COVID-19-Negative Inpatients With Diabetes: A Nationwide Study.
    Diabetes Care. 2021 Jul 7. pii: dc20-2350. doi: 10.2337/dc20-2350.
    PubMed        

  12. FAHRMANN ER, Adkins L, Driscoll HK
    Modification of the Association Between Severe Hypoglycemia and Ischemic Heart Disease by Surrogates of Vascular Damage Severity in Type 1 Diabetes During approximately 30 Years of Follow-up in the DCCT/EDIC Study.
    Diabetes Care. 2021 Jul 7. pii: dc20-2757. doi: 10.2337/dc20-2757.
    PubMed         Abstract available


    Diabetes Obes Metab

  13. KOH ES, Han K, Nam YS, Wittbrodt ET, et al
    Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea).
    Diabetes Obes Metab. 2021;23:455-466.
    PubMed         Abstract available

  14. CLEMMENSEN KKB, Blond MB, Amadid H, Bruhn L, et al
    No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial.
    Diabetes Obes Metab. 2021;23:530-539.
    PubMed         Abstract available

  15. KOOMEN JV, Stevens J, Bakris G, Correa-Rotter R, et al
    Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
    Diabetes Obes Metab. 2021;23:561-568.
    PubMed         Abstract available

  16. POTTEGARD A, Lund LC, Henriksen DP, Folkestad L, et al
    Use of dipeptidyl peptidase-4 inhibitors and risk of splanchnic vein thrombosis: A Danish nationwide new-user active comparator cohort study.
    Diabetes Obes Metab. 2021;23:648-652.
    PubMed         Abstract available

  17. ITO J, Nogami M, Morita Y, Sakaguchi K, et al
    Dose-dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by (18) F-labelled fluorodeoxyglucose positron emission tomography-MRI.
    Diabetes Obes Metab. 2021;23:692-699.
    PubMed         Abstract available

  18. O'HARA DV, Parkhill TR, Badve SV, Jun M, et al
    The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
    Diabetes Obes Metab. 2021;23:763-773.
    PubMed         Abstract available

  19. LEELARATHNA L, Choudhary P, Wilmot EG, Lumb A, et al
    Hybrid closed-loop therapy: Where are we in 2021?
    Diabetes Obes Metab. 2021;23:655-660.
    PubMed         Abstract available

  20. SILVERII GA, Monami M, Mannucci E
    Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2021;23:1052-1056.
    PubMed         Abstract available

  21. PATOULIAS D, Papadopoulos C, Doumas M
    Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials.
    Diabetes Obes Metab. 2021;23:1063-1065.
    PubMed        

  22. SUN JW, Hernandez-Diaz S, Bourgeois FT, Haneuse S, et al
    Antidiabetic medication use in commercially insured children and adolescents in the United States from 2004 to 2019.
    Diabetes Obes Metab. 2021;23:444-454.
    PubMed         Abstract available

  23. NEUEN BL, Arnott C, Perkovic V, Figtree G, et al
    Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
    Diabetes Obes Metab. 2021;23:382-390.
    PubMed         Abstract available

  24. CAHN A, Wiviott SD, Mosenzon O, Murphy SA, et al
    Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
    Diabetes Obes Metab. 2021;23:29-38.
    PubMed         Abstract available

  25. SALAHUDDIN T, Richardson V, McNeal DM, Henderson K, et al
    Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
    Diabetes Obes Metab. 2021;23:97-105.
    PubMed         Abstract available

  26. DANDONA P, Dhindsa S, Ghanim H, Saad F, et al
    Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review.
    Diabetes Obes Metab. 2021;23:18-28.
    PubMed         Abstract available

  27. HAMEED S, Salem V, Alessimii H, Scholtz S, et al
    Imperial Satiety Protocol: A new non-surgical weight-loss programme, delivered in a health care setting, produces improved clinical outcomes for people with obesity.
    Diabetes Obes Metab. 2021;23:270-275.
    PubMed         Abstract available

  28. GUENSCH DP, Tripyla A, Fischer K, Vogt AP, et al
    First insights into the performance of the Dexcom G6 continuous glucose monitoring system during cardiac surgery using hypothermic extracorporal circulation.
    Diabetes Obes Metab. 2021;23:294-295.
    PubMed        

  29. OKUNRINTEMI V, Mishriky BM, Powell JR, Cummings DM, et al
    Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
    Diabetes Obes Metab. 2021;23:276-280.
    PubMed         Abstract available

  30. WERNER U, Tennagels N, Fanelli CG, Bolli GB, et al
    Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.
    Diabetes Obes Metab. 2021;23:166-174.
    PubMed         Abstract available

  31. MASHAYEKHI M, Wilson JR, Jafarian-Kerman S, Nian H, et al
    Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal.
    Diabetes Obes Metab. 2021;23:281-286.
    PubMed         Abstract available

  32. GERSTEIN HC, Branch K, Heenan L, Del Prato S, et al
    Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist.
    Diabetes Obes Metab. 2021;23:318-323.
    PubMed         Abstract available

  33. ROTH CL, Perez FA, Whitlock KB, Elfers C, et al
    A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.
    Diabetes Obes Metab. 2021;23:363-373.
    PubMed         Abstract available

  34. SHAH M, Stolbov L, Yakovleva T, Tang W, et al
    A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes.
    Diabetes Obes Metab. 2021;23:991-1000.
    PubMed         Abstract available

  35. YAMASAKI N, Tamura Y, Kaga H, Sato M, et al
    A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium-glucose co-transporter-2 inhibitor tofogliflozin.
    Diabetes Obes Metab. 2021;23:1092-1100.
    PubMed         Abstract available

  36. CHERUBINI V, Rabbone I, Berioli MG, Giorda S, et al
    Effectiveness of a closed-loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: a prospective multicenter real-life study.
    Diabetes Obes Metab. 2021 Jul 6. doi: 10.1111/dom.14491.
    PubMed         Abstract available

  37. SARMA S, Sockalingam S, Dash S
    Obesity as a multisystem disease: Trends in obesity rates and obesity-related complications.
    Diabetes Obes Metab. 2021;23 Suppl 1:3-16.
    PubMed         Abstract available

  38. NASSIF ME, Windsor SL, Tang F, Husain M, et al
    Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial.
    Diabetes Obes Metab. 2021;23:1426-1430.
    PubMed         Abstract available

  39. SNITKER S, Andersen A, Berg B, van Marle S, et al
    Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
    Diabetes Obes Metab. 2021;23:1415-1419.
    PubMed         Abstract available

  40. TOLEDO FGS, Miller RG, Helbling NL, Zhang Y, et al
    The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial.
    Diabetes Obes Metab. 2021;23:1252-1261.
    PubMed         Abstract available

  41. HE Y, Pachori A, Chen P, Ma S, et al
    Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trial.
    Diabetes Obes Metab. 2021;23:1182-1190.
    PubMed         Abstract available

  42. CHILTON RJ
    Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.
    Diabetes Obes Metab. 2021;23:1215-1218.
    PubMed        

  43. GARFIELD V, Farmaki AE, Eastwood SV, Mathur R, et al
    HbA1c and brain health across the entire glycaemic spectrum.
    Diabetes Obes Metab. 2021;23:1140-1149.
    PubMed         Abstract available

  44. CARIOU B, Byrne CD, Loomba R, Sanyal AJ, et al
    Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.
    Diabetes Obes Metab. 2021;23:1069-1083.
    PubMed         Abstract available


    Diabetologia

  45. TREMBLAY J, Haloui M, Attaoua R, Tahir R, et al
    Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.
    Diabetologia. 2021 Jul 6. pii: 10.1007/s00125-021-05491.
    PubMed         Abstract available


    Invest Ophthalmol Vis Sci

  46. AMATO R, Lazzara F, Chou TH, Romano GL, et al
    Diabetes Exacerbates the Intraocular Pressure-Independent Retinal Ganglion Cells Degeneration in the DBA/2J Model of Glaucoma.
    Invest Ophthalmol Vis Sci. 2021;62:9.
    PubMed         Abstract available


    J Clin Endocrinol Metab

  47. FREESE J, Al-Rawi R, Choat H, Martin A, et al
    Proinsulin to C-peptide Ratio in the First Year Post Diagnosis of Type 1 Diabetes.
    J Clin Endocrinol Metab. 2021 Jul 6. pii: 6316148. doi: 10.1210.
    PubMed         Abstract available


    J Diabetes Complications

  48. CHAI TYL, Rajaratnam RM, Deng D, George J, et al
    The prevalence of gestational diabetes mellitus in women diagnosed with non-alcoholic fatty liver disease during pregnancy: A systematic review and meta-analysis.
    J Diabetes Complications. 2021 Jun 27:107991.
    PubMed         Abstract available

  49. LIN L, Dekkers IA, Huang L, Tao Q, et al
    Renal sinus fat volume in type 2 diabetes mellitus is associated with glycated hemoglobin and metabolic risk factors.
    J Diabetes Complications. 2021 Jun 15:107973.
    PubMed         Abstract available

  50. VENKATESAN P, Varghese J, Arthi TS, James JV, et al
    Evidence of dysregulated iron homeostasis in newly diagnosed diabetics, but not in pre-diabetics.
    J Diabetes Complications. 2021 Jun 19:107977.
    PubMed         Abstract available


    J Hypertens

  51. NUYUJUKIAN DS, Zhou JJ, Koska J, Reaven PD, et al
    Refining determinants of associations of visit-to-visit blood pressure variability with cardiovascular risk: results from the Action to Control Cardiovascular Risk in Diabetes Trial.
    J Hypertens. 2021 Jul 6. pii: 00004872-900000000-96635.
    PubMed         Abstract available


    J Nutr

  52. JAMES PT, Ali Z, Armitage AE, Bonell A, et al
    The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review.
    J Nutr. 2021 May 12. pii: 6274856. doi: 10.1093.
    PubMed         Abstract available

  53. LAOUALI N, Shah S, MacDonald CJ, Mahamat-Saleh Y, et al
    BMI in the Associations of Plant-Based Diets with Type 2 Diabetes and Hypertension Risks in Women: The E3N Prospective Cohort Study.
    J Nutr. 2021 Jun 3. pii: 6291874. doi: 10.1093.
    PubMed         Abstract available


    Lancet

  54. NAZZAL Z, Khatib B, Al-Quqa B, Abu-Taha L, et al
    The prevalence and risk factors of urinary incontinence among women with type 2 diabetes in the north West Bank: a cross-sectional study.
    Lancet. 2021;398 Suppl 1:S42.
    PubMed         Abstract available

  55. AFIFI T, Obeid M, Abdelati M, Almoqaid A, et al
    WHO/International Society of Hypertension risk prediction charts versus the UK Prospective Diabetes Study risk engine for cardiovascular risk assessment among patients with type 2 diabetes: a comparative study.
    Lancet. 2021;398 Suppl 1:S3.
    PubMed         Abstract available

  56. ATALLAH SM, Al-Jaghbir MT, Zayed AA
    The prevalence of diabetic peripheral neuropathy among diabetic Palestinian refugees in the Nuzha area, Jordan: a cross-sectional study.
    Lancet. 2021;398 Suppl 1:S15.
    PubMed         Abstract available


    Metabolism

  57. CHEN J, Zhang Q, Liu D, Liu Z, et al
    Exosomes: advances, development and potential therapeutic strategies in diabetic nephropathy.
    Metabolism. 2021 Jul 1:154834. doi: 10.1016/j.metabol.2021.154834.
    PubMed         Abstract available


    Pediatr Diabetes

  58. TREMBLAY ES, Ruiz J, Dykeman B, Maldonado M, et al
    Hispanic Caregivers' Experience of Pediatric Type 1 Diabetes: A Qualitative Study.
    Pediatr Diabetes. 2021 Jul 7. doi: 10.1111/pedi.13247.
    PubMed         Abstract available


    PLoS Med

  59. PISHGAR F, Shabani M, Quinaglia A C Silva T, Bluemke DA, et al
    Adipose tissue biomarkers and type 2 diabetes incidence in normoglycemic participants in the MESArthritis Ancillary Study: A cohort study.
    PLoS Med. 2021;18:e1003700.
    PubMed         Abstract available


    PLoS One

  60. YU CH, McCann M, Sale J
    "In my age, we didn't have the computers": Using a complexity lens to understand uptake of diabetes eHealth innovations into primary care-A qualitative study.
    PLoS One. 2021;16:e0254157.
    PubMed         Abstract available

  61. LIU DW, Haq Z, Yang D, Stewart JM, et al
    Association between smoking history and optical coherence tomography angiography findings in diabetic patients without diabetic retinopathy.
    PLoS One. 2021;16:e0253928.
    PubMed         Abstract available


    Retina

  62. ARYA M, Sorour O, Chaudhri J, Alibhai Y, et al
    DISTINGUISHING INTRARETINAL MICROVASCULAR ABNORMALITIES FROM RETINAL NEOVASCULARIZATION USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.
    Retina. 2019 Oct 14. doi: 10.1097/IAE.0000000000002671.
    PubMed         Abstract available


    Transplant Proc

  63. YAMANAKA T, Nakayama-Iwatsuki K, Fujimoto S, Hirono N, et al
    All-in-One Silk Fibroin Sponge as the Vitrification Cryodevice of Rat Pancreatic Islets and the VEGF-Embedded Scaffold for Subrenal Transplantation.
    Transplant Proc. 2021 May 26. pii: S0041-1345(21)00260.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: